Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. [electronic resource]
Producer: 20121219Description: 3640-7 p. digitalISSN:- 1527-7755
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Confidence Intervals
- Disease-Free Survival
- Docetaxel
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Neoplasm Invasiveness -- pathology
- Neoplasm Staging
- Platinum -- therapeutic use
- Prognosis
- Proportional Hazards Models
- Prospective Studies
- Receptors, Vascular Endothelial Growth Factor
- Recombinant Fusion Proteins -- therapeutic use
- Risk Assessment
- Survival Analysis
- Taxoids -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.